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1g5g. T HE EFFECTIVENESS OF LEVARTERENOL ;zS a teI-IlpOIXy treatment during hemorrhagic hypotension has been previously shown by this laboratory (I). The present study was undertaken to evaluate the effectiveness of levarterenol in restoring responsiveness to whole blood therapy in dogs submitted to prolonged hemorrhagic hypotension.
MATERIALS AND METHODS
Inbred beagle hounds and mongrel dogs (mean weight = 9.7 kg; range 6.1-12.4 kg) were used in the experiments.
The methods employed for the measurements of arterial blood pressure, red cell mass, plasma volume, hepatic clearance of rose bengal and hematocrit are described in detail elsewhere (2, 3) . The whole blood clearance of radioactive (1131) Diodrast was used as an index of renal blood flow (Fozzard and Gilmore, manuscript in preparation) .
In given a glucose-saline drip placebo and the other levarterenol in glucose-saline, the dog to receive therapy having been chosen prior to reinfusion by the flip of a coin. The levarterenol drip was adjusted to a rate necessary to maintain mean arterial pressure at approximately IOO mm Hg and the placebo was given at the same rate as the levarterenol.
The drug infusion was discontinued when arterial pressure was maintained at this pressure level spontaneously.
The measurements obtained during the control period were repeated as soon as arterial pressure had stabilized following blood replacement, and 4-6 hours later. Tetracycline (250 mg) was in some cases given intravenously to both control and treated animals after blood replacement. Survival in hours was measured from the time of blood volume replacement.
For statistical purposes all animals alive after 24 hours were credited with a 24-hour survival, and no attempt was made to treat animals after this time.
RESULTS
Survival. There was a significant difference (X2 = 8.7; P < . OI) in survival between the placeboand the levarterenol-treated animals. The average survival time of the levarterenol animals was I 5.5 If 8.9 hours and that of the placebo, 5.7 ZfI: 6. I hours (table I) . Six of the twelve lcvarterenol-treated and only one of the eleven placebo animals survived greater than 24 hours.
Blood volume. When compared with the prehemorrhage levels in both groups, plasma volume showed a significant decrease and red cell mass and FCen ratio showed no change during the postinfusion period ( The significantly reduced rose bengal clearance values after adequate blood volume replacement suggest reduced liver blood flow. However, Zweifach and Benacerraf (9) have recently shown that following sustained hemorrhage and reinfusion of blood, the clearance rate of chromic phosphate is significantly reduced although blood flow through the liver is restored. These authors suggest that under these conditions there is either an impairment of Kupffer cell activity or a shunting of blood through pathways in the periphery of the liver lobule. If rose bengal and chromic phosphate are cleared by the liver in the same manner, it is possible that the reduced rose bengal clearance during the postinfusion period was produced by one of the above mechanisms rather than by an actual decrease in liver blood flow.
It show the efficacy of levarterenol in increasing the survival of hemorrhaged rats unresponsive to blood volume replacement.
These authors employed a method for inducing shock similar to that used during the present study and initiated therapy immediately after blood replacement.
The period of time (36 hr.) that the rats had to be maintained on the drug to effect differences in survival over untreated rats was probably a reflection of the lower pressure (30 mm Hg) at which they were maintained during oligemia. Subsequently Lansing and Stevenson (6) studied the response to levarterenol administration in dogs utilizing the same experimental design. They found a greater survival in those animals receiving levarterenol than in placebo-treated dogs, but the difference was not statistically significant.
In the placebo-treated animals cardiac output fell markedly with the progression of shock, but in the treated dogs this fall was not seen. The authors concluded that levarterenol was beneficial in this type of injury and that it exerted its beneficial effect on cardiac output by a direct action on the heart. Frank and co-workers (7), however, reported that levarterenol was ineffective in reversing the unresponsiveness to blood replacement following oligemic hypotension in the dog. In their study, oligemia was maintained longer (4.5 hr.) than in the present experiments and therapy was begun following blood replacement only after blood pressure had fallen to 60 mm Hg. 
